Professional Documents
Culture Documents
Members Signin
ABOUT BAYBIO
GET INVOLVED
BIOMEDevice Forum
EVENT CENTER
BIOMEDevice Forum is the nation’s premier executivelevel conference focusing on convergence and cross sector
BAYBIO CALENDAR collaborations among companies in the biotechnology, medical device, IVD, and pharmaceutical industries. This two day
event brings together key players involved in investing, partnering, licensing, and developing business opportunities in
COMMUNITY CALENDAR the rapidly growing market for innovative healthcare products.
WEB BROADCASTS REGISTER FOR THE EVENT
ARCHIVED EVENTS
WEDNESDAY, SEPTEMBER 10, 2008
BayBio Open House 103008
8:45 Chair's Opening Remarks
Breakthroughs in Lung Cancer
Therapy Technology
State and National Tax Changes
9:00 9:45 Keynote Converging Visions
Gene Acres 16: Managing Risk Convergent medical technologies are transforming healthcare as we currently know it through
Leveraging Opportunities crosssector collaborations of biotechnology, medical device, pharmaceutical, diagnostics, and
Developing Treatments for Ovarian information technologies industries. Examine the opportunities convergence has to offer the life
Cancer sciences.
Accelerated Commercialization: Dr. Mike Samoszuk, Chief Medical Officer, Roche Diagnostics
Lessons Learned
9:45 10:30 The Future of Convergence in Clinical Medicine
BIOMEDevice Forum This session addresses the growing role of convergent technology in the context of the evolving
2008 Candidate Forum practice of clinical medicine with a focus, in particular, on personalized medicine, improved safety,
and expanded capabilities. Examine convergent technology challenges from the perspective of the
Advances in Cardiac Care clinician. Discover how convergence impacts the clinicians and patients in a variety of clinical areas.
Intelligent Choices in Breast Cancer Hear what physicians need and how it compares to what they are currently receiving.
Hepatitis C: in Search of a Cure Moderator:
Reimbursement Ogan Gurel, MD, Aesis Group
Fighting Breast Cancer Panelists:
BayBio2008: Doing Well by Doing John Lopez MD, Director, Cardiac Catheterization Laboratory, University of Chicago Hospitals
Right
Gokhan Mutlu MD, Assistant Professor, Division of Pulmonary & Critical Care,
BioBasics Briefing 112008 Northwestern University
Combination Products
Pierre Gobin, MD, Professor of Radiology in Neurology and Neurosurgery Director, Interventional
BioBasics Briefing Neuroradiology, Weill Cornell Medical College of New York Presbyterian Hospital
BayBio Solutions
M. Bret Schneider, MD, Consulting Assistant Professor, Department of Psychiatry, Department of
CEO Roundtable Neurosurgery, Stanford University School of Medicine
Alternative Financing
Geoffrey Gurtner, MD, Professor of Surgery, Division of Plastic Surgery and Reconstruction,
Trends in Creative Pharma Stanford University School of Medicine
Partnerships
10:30–11:00 Networking Break
When is it Time to Sell?
11:00 11:45 Convergent Technologies: Challenges and Opportunities
BayBio Holiday Soiree 2007 Explore technological timeline and differential effectiveness in terms of convergence activities. Hear
BioBasics Briefing which new technologies are effective and which are not, and how new technologies have affected
business structures of the cross sector collaborations among biotechnology, medical device,
2007 Pantheon Ceremony pharmaceutical, and IVD industries.
Presenting DiNA Awards
BIOMEDevice George Poste, Director, BioDesign Institute
Biotech Primer Dennis Goldberg, President & CEO, Transport Pharmaceuticals
Bay Bio Pantheon Awards 2006
Collaborations
Gene Acres 2006: Building
Successful Life Science Facilities 2:45 3:45 Structuring Effective Partnerships
Election Results Town Hall Cross sector collaborations are being utilized to achieve sustainable pipelines, continued
profitability, and advancements in healthcare. Different business models are used in each of the
BayBio2006: Accelerating Global converging industries. Enhance your understanding of the values of the various industries and
Leadership examine the challenges and opportunities of cross sector partnerships.
TriCities Roundtable
Copresenters:
BayBioNEST’s Holiday Celebration of Michael Dunn, Vice President Business Development and Chief Business Officer,
Scientific Exploration and Monogram Biosciences
Achievement
Stephen Dahms, PhD, President and CEO, Alfred E. Mann Foundation for Biomedical Engineering
2005 BayBio Pantheon Awards
The Patenting of Life Forms 3:45 4:30 Benchmarking Convergent Medical Technology Partnerships
Discuss critical issues impacting the success of cross sector collaborations. Determine
2005 BayBioNEST Life Sciences benchmarks for different business models that will allow you to establish a successful combination
Entrepreneur & Investor Roundtables product partnership strategy.
CIRM Scientific Meeting October 2005
Scott Taper, Analyst, Nerac
Gene Acres 2005
4:30 Chair's Closing Remarks
The Business and Financing of Stem
Cell Research in California Thursday, September 11, 2008
HR issues in Human Infrastructure
9:00 Chair's Opening Remarks
BayBio2005: Returns on Innovation
Choosing & Managing Vendors / Regulatory
Tools for Controlling Resources
9:15 10:00 FDA Keynote
March 2005 Entrepreneur & Investor
Roundtables Frank M. Torti, Principal Deputy Commissioner and Chief Scientist, FDA
Investor Roundtables 10:00 10:45 Navigating the Regulatory Landscape for Combination Products
The VCynic Syndicate 2005 Examine the unique regulatory challenges for convergent technologies required to navigate two FDA
quality systems. Hear from regulators and industry what’s needed, what’s on the way, and how to
Investor Roundtables best work together for accelerated approvals, while maintaining safety.
BayBioNEST: Investor & Entrepreneur
Roundtable Moderator:
Bradley Merrill Thompson, Executive Director Combinations Products Coalition
Ready, Aim, Fire Strategies for Drug
Development Panelists:
Laboratories of Innovation 2004 Suzanne Kiani, Genentech
Radford 2004 Survey Presentation Geoffrey Levitt, Vice President and Chief Counsel, Regulatory and Research, Wyeth
Ready, Aim, Fire
10:45 11:15 Networking Break
2004 BayBio Pantheon Awards
12:30 2:00 Lunch
Holiday Soiree
BayBioNest: Holiday Soiree
Reimbursement
BIO 2004 Dennis Goldberg, President & CEO, Transport Pharmaceuticals
Gene Acres 2003
12:00 12:45 Examine the Economic Feasibility to Develop Convergent Products in Terms of Reimbursement
Gene Acres 2002 Identify the key economic considerations to determine entry into crosssector collaboration.
Enhance your understanding of evidence based medicine with regard to the economics of
Gene Acres 2001
reimbursement for combination products. Address issues of cost effectiveness and improved
Gene Acres 2000 health outcomes necessary to achieve reimbursement.
BayBio Nest: Launch
Nancy L. Reaven, President, Strategic Health Resources
ARCHIVED PRESENTATIONS
12:45 Lunch
MEDIA REGISTRATION
Intellectual Property/Finance
MEMBER CENTER
2:15 3:00 Market Growth
INFORMATION CENTER Combination products are designed to increase efficacy, improve adherence due to ease of use,
extend the lifecycle of the product, and improve health outcomes. Of new products currently in
MEDIA CENTER development, thirty percent are combination products. Revenue for combination products continues
to rise, but where are the areas of growth for combination products?
CAREER CENTER
Eduardo Schur, Managing Director, Navigant Consulting
Intellectual Property/Finance
3:00 3:45 Intellectual Property
Examine the intellectual property issues unique to combination products. Hear the key
considerations of venture capitalists surrounding intellectual property of convergent medical
technologies. Discuss how to adapt your intellectual property strategies with the ever changing
legislative rulings.
Moderator:
Walter Wu, Associate, Morrison & Foerster
Panelists:
William C. Revelos, General Counsel, Zeltiq Aesthetics
Sanjay S. Bagade, Partner, Levine Bagade Han, LLP
Additional Panelist To Be Announced
3:45 4:30 Positioning for Investment
Hear the insider’s perspective in assessing value and risk of a combination product. What are the
key considerations when it comes to investing in a combination product for venture capitalists and
angel investors?
Moderator:
Moderator to be announced
Panelists:
Ken Andrews, CEO & President, Histogenics
Leslie Bortorff, General Partner, Medical Technology, RoederJohnson Corporation
Nandini Tandon, PhD, Managing Director, Lumira Capital
4:30 Chair's Closing Remarks
BayBio 395 Oyster Point Blvd. Suite 117 South San Francisco CA 94080 Tel: (650)871 7101